Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...
ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst Michael Schmidt reaffirmed his Buy rating on ADC Therapeutics (NYSE:ADCT) ...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...
After layoffs this fall, Mythic Therapeutics is winding down, putting all its assets up for sale and terminating its only ...
SurvivorNet on MSN
New FDA approved drug combo offers HER2-positive metastatic breast cancer patients hope
For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
“These findings by our University of Hawai‘i Cancer Center research team show that drug resistance is not necessarily the end ...
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has ...
The Chosun Ilbo on MSN
Dong-A Socio Group targets global market with CDMO, ADC platforms
Dong-A Socio Group is targeting the global market with a diversified strategy encompassing new drug development, raw ...
Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan ...
Learn about women in STEM and the vital role of Dr Lidia Serina in advancing biopharma therapies and empowering women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results